Arvinas, Pfizer Seek FDA Approval of Vepdegestrant in Breast Cancer

Published: 2025-06-06 08:08:08 ET ARVN

Published on 06/06/2025 at 08:08, updated on 06/06/2025 at 08:09

By Colin Kellaher

Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations.

Arvinas on Friday said the application covers vepdegestrant in patients with ER-positive/human epidermal growth factor receptor 2-negative ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy.

Clinical-stage biotechnology company Arvinas and drugmaker Pfizer in 2021 announced plans to collaborate on the development and commercialization of vepdegestrant, with the companies to share expenses and profits.

Write to Colin Kellaher at [email protected]

(END) Dow Jones Newswires

06-06-25 0807ET